首页> 美国卫生研究院文献>Canadian Journal of Gastroenterology >Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review
【2h】

Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review

机译:内镜与经皮胆道引流术治疗晚期恶性肺门梗阻的临床分析:Meta分析和系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Palliation in advanced unresectable hilar malignancies can be achieved by endoscopic (EBD) or percutaneous transhepatic biliary drainage (PTBD). It is unclear if one approach is superior to the other in this group of patients. Aims. Compare clinical outcomes of EBD versus PTBD. Methods. (i) Study Selection Criterion. Studies using PTBD and EBD for palliation of advanced unresectable hilar malignancies. (ii) Data Collection and Extraction. Articles were searched in Medline, PubMed, and Ovid journals. (iii) Statistical Method. Fixed and random effects models were used to calculate the pooled proportions. Results. Initial search identified 786 reference articles, in which 62 articles were selected and reviewed. Data was extracted from nine studies (N = 546) that met the inclusion criterion. The pooled odds ratio for successful biliary drainage in PTBD versus EBD was 2.53 (95% CI = 1.57 to 4.08). Odds ratio for overall adverse effects in PTBD versus EBD groups was 0.81 (95% CI = 0.52 to 1.26). Odds ratio for 30-day mortality rate in PTBD group versus EBD group was 0.84 (95% CI = 0.37 to 1.91). Conclusions. In patients with advanced unresectable hilar malignancies, palliation with PTBD seems to be superior to EBD. PTBD is comparable to EBD in regard to overall adverse effects and 30-day mortality.
机译:背景。晚期无法切除的肺门恶性肿瘤可通过内窥镜检查(EBD)或经皮肝穿刺胆道引流术(PTBD)缓解。目前尚不清楚在这一组患者中,一种方法是否优于另一种方法。目的比较EBD与PTBD的临床结局。方法。 (i)研究选择标准。使用PTBD和EBD缓解晚期无法切除的肝门恶性肿瘤的研究。 (ii)数据收集和提取。在Medline,PubMed和Ovid期刊上搜索文章。 (iii)统计方法。固定效应和随机效应模型用于计算合并比例。结果。初步搜索确定了786篇参考文章,其中选择和审查了62篇文章。从符合纳入标准的九项研究(N = 546)中提取数据。 PTBD与EBD胆道引流成功的合并比值比为2.53(95%CI = 1.57至4.08)。 PTBD组与EBD组的总体不良反应几率为0.81(95%CI = 0.52至1.26)。 PTBD组与EBD组的30天死亡率之比为0.84(95%CI = 0.37至1.91)。结论。在晚期无法切除的肺门恶性肿瘤患者中,PTBD的镇静作用似乎优于EBD。在总体不良反应和30天死亡率方面,PTBD与EBD相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号